Key highlights
- Argent BioPharma rose 11.11% to $0.020, Kalina Power rose 9.09% to $0.012 and Aeeris rose 9.62% to $0.057 at 11:04 AM AEDT on 19 November 2026.
- Argent BioPharma licensed four cannabis genotypes on a 10-year exclusive worldwide basis, with a 15% Royalty on profits.
- Kalina Power reported about A$11.4 million of cash and no debt, with five secured gas-fired power projects in Alberta.
Three small-cap ASX companies gained in mid-morning trade on 19 November 2026, with the S&P/ASX 200 up 0.83% at 8,748.30 around midday. Argent BioPharma Ltd (ASX:RGT) traded at $0.020, up 11.11%. Kalina Power Limited (ASX:KPO) traded at $0.012, up 9.09%, and Aeeris Ltd (ASX:AER) traded at $0.057, up 9.62%. The three companies operate in pharmaceutical licensing, Canadian power development and enterprise weather software, and each has a recent operating update. The figures quoted are intraday prices at 11:04 AM AEDT on 19 November 2026, reflecting trade in progress at that time rather than closing prices. Each share price is shown as traded during the session, so later moves may differ from the figures quoted here. The S&P/ASX 200 figures are the level and percentage change quoted at midday on the same day. The companies named in this article are each covered in their own section below, with the release date for the update shown where it applies. Investors reading these figures should note that the prices are from the Trading session and do not represent a closing price for the day.
Argent BioPharma (ASX:RGT): Cannabis Genetics Licence
Argent BioPharma announced on 27 October 2026 a 10-year exclusive worldwide licence with Thai Phytomed International covering four proprietary cannabis genotypes, MXC-THC-10/3, MXC-THC-81/5, MXC-THC-40/3 and MXC-THC-40/2. The licensee receives rights to cultivate, process, manufacture and sell products from those genetics, while Argent keeps ownership of the underlying genetics and intellectual property. Argent will receive a royalty of 15% of profits from commercialisation, calculated quarterly. The licence does not cover the company's other pharmaceutical products, including CannEpil and CimetrA.
The licence covers rights to cultivate, process, extract, manufacture, market, distribute and sell products from the four genotypes, including flower, extracts and cannabinoid active pharmaceutical ingredients. Argent may end the licence if no commercial sale has been made within 24 months after delivery of the genetic material, and it keeps the right to use the genetics for internal research.
Kalina Power (ASX:KPO): Alberta Power Projects
Kalina Power reported on 30 October 2026 that it holds five secured gas-fired power projects in Alberta, Canada, intended to serve large loads such as AI data centres. Alberta data centre power applications exceeded 16 gigawatts during the quarter. The company said its Clusters 2 and 3 projects are advancing through the AESO queue, with its larger projects positioned for in-service dates of calendar 2029. It reported about A$11.4 million of cash, no Debt and a relatively low Burn Rate at 30 September 2026.
Kalina said its five secured projects represent an early mover advantage, with more sites being pursued. The company noted that federal and Alberta governments have established policies to position the province as a premier destination for data centres, including amendments that remove gas-fired power plants from the federal impact assessment list.
Aeeris (ASX:AER): Recurring Revenue Repositioning
Aeeris reported in its quarterly activities report dated 28 October 2026 that Annual Recurring Revenue closed the September quarter at $3,493,530, down 1.4% on the prior corresponding period. The company completed its exit from a reseller Partnership and ceased non-core climate-science revenue, which it says lowered ARR by $509,000. Annual revenue per customer rose 10.0% to $21,173. Unaudited quarterly revenue was $975,191, and the company reported cash of $1.02 million with no debt.
Contracts re-signed by former reseller customers are expected to go live in the second quarter of FY27 and are not included in reported ARR at 30 September 2026. Fixed ARR was 91.5% of total ARR, and 99.1% of Accounts Receivable were under 30 days, according to the report.






Please wait processing your request...